Clinical Trial Update: A Study to Evaluate TMI-358 in the Treatment of Distal Subungual Onychomycosis [Phase 2]

View source ↗

Summary

The Phase 2 trial of TMI-358 for distal subungual onychomycosis was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Distal Subungual Onychomycosis

Drugs mentioned

• TMI-358

Snippet

Sponsor: Talima Therapeutics, Inc. | Conditions: Distal Subungual Onychomycosis | Phase 2 | Status: TERMINATED